Estimates suggest that 48 million couples live with infertility globally.
Diagnoses male-factor infertility to assist the clinician direct to the suitable IVF treatment.
Current commercial methods to analyse the sperm quality only look into the physical aspects of the sperm. Spermosens is developing first of its kind automated sperm diagnostic device JUNO-Checked that relies of their ability to bind to egg cell-proteins. The approach will, for the first time, enable detection of fertilization capacity of sperms, and hence choice of the appropriate IVF treatment method.
Spermosens aims at reducing the conventional iterations in IVF treatments to achieve pregnancy with JUNO-Checked.
OF INFERTILITY CASES WITH A MALE FACTOR1
DECREASE IN SPERM COUNT SINCE 1970s IN WESTERN MALES2
UNEXPLAINED MALE INFERTILITY3
IVF CYCLES PERFORMED ANNUALLY GLOBALLY4
SUCCESS RATES IN ART PER ASPIRATION5
- Whereof 1 million in Europe. https://academic.oup.com/hropen/article/2021/3/hoab026/6342525
- Ref: ESHRE ART Fact Sheet 2022
A patented, user friendly, rapid and small footprint Diagnostic System which predicts the fertilization capacity of sperms. This will assist the clinicians and embryologists to individually decide if the suitable treatment is standard-IVF or ICSI.
Millions of couples waiting in queue for 1-3 years for IVF can now be helped quicker and more economically.
Breakthrough Platform technology
This will lead to an immediate decision if the sperm sample is suitable for standard-IVF or ICSI, thus drastically limiting the number of cycles required for fertilisation and reducing the burden of infertility on the female partner.
Get the latest news by signing up to our newsletter. We welcome you to contact us with any thoughts you may have.